LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
1.74
USD
Market Closed
Market Cap:
$45.8m
Balance Sheet
Balance Sheet Decomposition
LAVA Therapeutics NV
LAVA Therapeutics NV
Balance Sheet Decomposition is not available for
LAVA Therapeutics NV
LAVA Therapeutics NV
Balance Sheet
LAVA Therapeutics NV
LAVA Therapeutics NV
Currency: USD
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & Cash Equivalents |
7
|
15
|
14
|
90
|
34
|
0
|
|
| Cash |
7
|
15
|
14
|
90
|
34
|
0
|
|
| Short-Term Investments |
0
|
1
|
119
|
43
|
62
|
0
|
|
| Total Receivables |
0
|
2
|
1
|
3
|
2
|
0
|
|
| Accounts Receivables |
0
|
1
|
0
|
3
|
1
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
3
|
4
|
3
|
3
|
|
| Total Current Assets |
8
|
18
|
137
|
141
|
99
|
79
|
|
| PP&E Net |
1
|
2
|
2
|
2
|
2
|
1
|
|
| PP&E Gross |
1
|
2
|
2
|
2
|
2
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
2
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
1
|
0
|
0
|
|
| Total Assets |
9
N/A
|
21
+133%
|
139
+579%
|
143
+3%
|
102
-29%
|
81
-21%
|
|
| Liabilities | |||||||
| Accounts Payable |
0
|
1
|
3
|
4
|
4
|
3
|
|
| Accrued Liabilities |
1
|
1
|
2
|
8
|
5
|
10
|
|
| Short-Term Debt |
0
|
0
|
0
|
5
|
5
|
5
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
5
|
7
|
5
|
0
|
0
|
|
| Total Current Liabilities |
1
|
7
|
11
|
22
|
15
|
18
|
|
| Long-Term Debt |
2
|
4
|
5
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
2
|
5
|
35
|
35
|
35
|
|
| Total Liabilities |
3
N/A
|
13
+330%
|
21
+62%
|
57
+175%
|
50
-13%
|
53
+6%
|
|
| Equity | |||||||
| Common Stock |
0
|
0
|
4
|
4
|
4
|
4
|
|
| Retained Earnings |
13
|
33
|
74
|
99
|
150
|
175
|
|
| Additional Paid In Capital |
19
|
41
|
192
|
194
|
208
|
212
|
|
| Other Equity |
0
|
1
|
4
|
13
|
11
|
13
|
|
| Total Equity |
6
N/A
|
8
+31%
|
118
+1 458%
|
86
-27%
|
51
-41%
|
28
-45%
|
|
| Total Liabilities & Equity |
9
N/A
|
21
+133%
|
139
+579%
|
143
+3%
|
102
-29%
|
81
-21%
|
|
| Shares Outstanding | |||||||
| Common Shares Outstanding |
25
|
25
|
26
|
26
|
26
|
26
|
|
Switch to:
Switch to:
See Also
Discover More
